1887

Abstract

Vaccination is the most efficacious procedure to curtail Porcine circovirus 2 (PCV2)-associated diseases (PCVAD). Experimental studies indicate that PCV2 vaccine-induced virus-neutralizing antibodies play a major role in protection from PCVAD. However, the immune response to PCV2 vaccination of pigs on farms is less clear. Analysing groups of age-matched vaccinated and non-vaccinated farmed pigs, we found significantly increased levels of virus-neutralizing antibodies only in vaccinated pigs belonging to the age group with the highest risk for developing PCVAD. Serum levels of PCV2 genomes were not different between corresponding age groups. Levels of antibodies directed against a linear peptide from the PCV2 capsid protein correlated with those of virus-neutralizing antibodies and reached the highest levels in older, non-vaccinated animals, pointing towards an intense interaction between PCV2-infected cells and the immune system. In conclusion, current PCV2 vaccines are in need of improvement to induce stronger and more rapid immunity to prevent PCV2 infection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.000206
2015-09-01
2024-12-02
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/9/2743.html?itemId=/content/journal/jgv/10.1099/vir.0.000206&mimeType=html&fmt=ahah

References

  1. Beach N.M., Meng X.J. 2012; Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2). Virus Res 164:33–42 [View Article][PubMed]
    [Google Scholar]
  2. Cline G., Wilt V., Diaz E., Edler R. 2008; Efficacy of immunising pigs against porcine circovirus type 2 at three or six weeks of age. Vet Rec 163:737–740[PubMed]
    [Google Scholar]
  3. Ellis J. 2014; Porcine circovirus: a historical perspective. Vet Pathol 51:315–327 [View Article][PubMed]
    [Google Scholar]
  4. Eschbaumer M., Law S., Solis C., Chernick A., van der Meer F., Czub M. 2014; Rapid detection of neutralizing antibodies against bovine viral diarrhoea virus using quantitative high-content screening. J Virol Methods 198:56–63 [View Article][PubMed]
    [Google Scholar]
  5. Finsterbusch T., Mankertz A. 2009; Porcine circoviruses – small but powerful. Virus Res 143:177–183 [View Article][PubMed]
    [Google Scholar]
  6. Fort M., Olvera A., Sibila M., Segalés J., Mateu E. 2007; Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs. Vet Microbiol 125:244–255 [View Article][PubMed]
    [Google Scholar]
  7. Fort M., Sibila M., Allepuz A., Mateu E., Roerink F., Segalés J. 2008; Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins. Vaccine 26:1063–1071 [View Article][PubMed]
    [Google Scholar]
  8. Fort M., Sibila M., Pérez-Martín E., Nofrarías M., Mateu E., Segalés J. 2009a; One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model. Vaccine 27:4031–4037 [View Article][PubMed]
    [Google Scholar]
  9. Fort M., Fernandes L.T., Nofrarias M., Díaz I., Sibila M., Pujols J., Mateu E., Segalés J. 2009b; Development of cell-mediated immunity to porcine circovirus type 2 (PCV2) in caesarean-derived, colostrum-deprived piglets. Vet Immunol Immunopathol 129:101–107 [View Article][PubMed]
    [Google Scholar]
  10. Gerber P.F., Garrocho F.M., Lana A.M., Lobato Z.I. 2012; Fetal infections and antibody profiles in pigs naturally infected with porcine circovirus type 2 (PCV2). Can J Vet Res 76:38–44
    [Google Scholar]
  11. Gorres J.P., Lager K.M., Kong W.P., Royals M., Todd J.P., Vincent A.L., Wei C.J., Loving C.L., Zanella E.L., other authors. 2011; DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs. Clin Vaccine Immunol 18:1987–1995 [View Article][PubMed]
    [Google Scholar]
  12. Han K., Seo H.W., Oh Y., Park C., Kang I., Jang H., Chae C. 2013; Efficacy of a piglet-specific commercial inactivated vaccine against Porcine circovirus type 2 in clinical field trials. Can J Vet Res 77:237–240
    [Google Scholar]
  13. Harding J.C., Baker C.D., Tumber A., McIntosh K.A., Parker S.E., Middleton D.M., Hill J.E., Ellis J.A., Krakowka S. 2008; Porcine circovirus-2 DNA concentration distinguishes wasting from nonwasting pigs and is correlated with lesion distribution, severity, and nucleocapsid staining intensity. J Vet Diagn Invest 20:274–282 [CrossRef]
    [Google Scholar]
  14. Horlen K.P., Dritz S.,, Nietfeld J.C.,, Henry S.C.,, Hesse R.A.,, Oberst R.,, Hays M.,, Anderson J., Rowland R.R. 2008; A field evaluation of mortality rate and growth performance in pigs vaccinated against porcine circovirus type 2. JAVMA 232 906–912
    [Google Scholar]
  15. Jóźwik A., Manteufel J., Selbitz H.J., Truyen U. 2009; Vaccination against porcine parvovirus protects against disease, but does not prevent infection and virus shedding after challenge infection with a heterologous virus strain. J Gen Virol 90:2437–2441 [View Article][PubMed]
    [Google Scholar]
  16. Kekarainen T., McCullough K., Fort M., Fossum C., Segalés J., Allan G.M. 2010; Immune responses and vaccine-induced immunity against Porcine circovirus type 2. Vet Immunol Immunopathol 136:185–193 [View Article][PubMed]
    [Google Scholar]
  17. Kristensen C.S., Baadsgaard N.P., Toft N. 2011; A meta-analysis comparing the effect of PCV2 vaccines on average daily weight gain and mortality rate in pigs from weaning to slaughter. Prev Vet Med 98:250–258 [View Article][PubMed]
    [Google Scholar]
  18. Martelli P., Ferrari L., Morganti M., De Angelis E., Bonilauri P., Guazzetti S., Caleffi A., Borghetti P. 2011; One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Vet Microbiol 149:339–351 [View Article][PubMed]
    [Google Scholar]
  19. Meerts P., Misinzo G., Lefebvre D., Nielsen J., Bøtner A., Kristensen C.S., Nauwynck H.J. 2006; Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease. BMC Vet Res 2:6 [View Article][PubMed]
    [Google Scholar]
  20. Olvera A., Sibila M., Calsamiglia M., Segalés J., Domingo M. 2004; Comparison of porcine circovirus type 2 load in serum quantified by a real time PCR in postweaning multisystemic wasting syndrome and porcine dermatitis and nephropathy syndrome naturally affected pigs. J Virol Methods 117:75–80 [View Article][PubMed]
    [Google Scholar]
  21. Rose N., Opriessnig T., Grasland B., Jestin A. 2012; Epidemiology and transmission of porcine circovirus type 2 (PCV2). Virus Res 164:78–89 [View Article][PubMed]
    [Google Scholar]
  22. Segalés J., Kekarainen T., Cortey M. 2013; The natural history of porcine circovirus type 2: from an inoffensive virus to a devastating swine disease?. Vet Microbiol 165:13–20 [View Article][PubMed]
    [Google Scholar]
  23. Seo H.W., Oh Y., Han K., Park C., Chae C. 2012; Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge. BMC Vet Res 8:194 [View Article][PubMed]
    [Google Scholar]
  24. Trible B.R., Kerrigan M., Crossland N., Potter M., Faaberg K., Hesse R., Rowland R.R. 2011; Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease. Clin Vaccine Immunol 18:749–757 [View Article][PubMed]
    [Google Scholar]
  25. Trible B.R., Suddith A.W., Kerrigan M.A., Cino-Ozuna A.G., Hesse R.A., Rowland R.R. 2012; Recognition of the different structural forms of the capsid protein determines the outcome following infection with porcine circovirus type 2. J Virol 86:13508–13514 [View Article][PubMed]
    [Google Scholar]
/content/journal/jgv/10.1099/vir.0.000206
Loading
/content/journal/jgv/10.1099/vir.0.000206
Loading

Data & Media loading...

Supplements

Supplementary Data

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error